The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.
Lyon 69495, France
CHU de Saint-Etienne
Saint-Étienne 42055, France
Patient affiliated to a social security regimen or beneficiary of the same
Signed written informed consent form
Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.
Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
Patient whose follow-up or life expectancy is less than 6 months.
Study Contact Info
Contact Listings Owner Form
Biomarkers in Multiple Myeloma 0 reviewsWrite Your Review
There are no reviews yet.